Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease.
Decreased nitric oxide (NO) production and/or impaired NO bioavailability may occur in patients with chronic kidney disease (CKD), and could contribute to the elevation of blood pressure, cardiovascular disease (CVD) and the progression of renal injury in these patients. However, the underlying molecular mechanisms for reduced NO action in patients with CKD remains to be elucidated. Asymmetric dimethylarginine (ADMA) is a naturally occurring L-arginine analogue found in plasma and various types of tissues, acting as an endogenous NO synthase inhibitor in vivo. Further, plasma level of ADMA is elevated in patients with CKD and found to be a strong biomarker or predictor for future cardiovascular events. In addition, plasma level of ADMA could predict the progression of renal injury in these patients as well. These findings suggest that elevation of ADMA may be a missing link between CVD and CKD. In this review, we discuss the molecular mechanisms for the elevation of ADMA and its pathophysiological role for CVD in high-risk patients, especially focusing on patients with CKD.
Ueda
Seiji
S
Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan. ueda@med.kurume-u.ac.jp
Yamagishi
Sho-Ichi
S
Kaida
Yusuke
Y
Okuda
Seiya
S
D001120:Arginine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000502:physiology; D002318:Cardiovascular Diseases / Q000503:physiopathology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000503:physiopathology*
C487735:dimethylarginine; D001120:Arginine